hotspot -WSS

hotspot

author：explore 2025-09-28 23:11:48 - browse：4

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Extreme heat events are a public health emergency

hotspot

knowledge

WSS

FDA panel gives mixed vote on blood pressure devices

Diversify hospital leadership teams to protect BIPOC patient health

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

As pharma fights Medicare drug negotiation, hospitals, docs silent

FDA panel gives mixed vote on blood pressure devices

Apellis safety probe of eye disease drug centers on injection needle

focus

hotspot

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Free speech concerns arise in wake of journal editor Eisen's firing

Psychedelics group wrestles with new pharma identity

FDA approves Recor Medical high blood pressure device

State Dept. review finds Biden bears some blame for Afghanistan failures

How to make Best Hospitals ratings actually useful for patients

Dobbs anniversary: the lost opportunity of abortion as health care

CDC advisory panel says seniors 'may' get RSV vaccine

Trump demands the U.S. pay no more for drugs than other countries … again

MoonLake credibility takes another hit with mid

hotspot

Medicare solvency divides Republicans at the presidential debate

Study: New antibiotic targets gonorrhea as well as last existing drug

MoonLake credibility takes another hit with mid

NYU Langone launches private ChatGPT for its health care data

Study: New antibiotic targets gonorrhea as well as last existing drug

In science, is the line between industry and academia shifting?

entertainment

hotspot

knowledge

explore